June 11, 2026 BioInvent’s BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC (EHA 2026)
June 11, 2026 Best Gold IRA for Beginners 2026: Top Gold IRA Providers Ranked and Compared in New Report
June 11, 2026 BioInvent’s TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA(R) (pembrolizumab) in Advanced CTCL (EHA 2026)
